We’re in one of those markets where it seems like nothing is working. The pain starts early with the evening S & P and Nasdaq futures giving you a double dose of crimson. But the trusty S & P Short Range Oscillator isn’t oversold enough to hold your nose and buy something. So you just…
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health…
A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark | E+ | Getty Images Felix is five years old, loves food, and refuses to lose weight. His owner, Amy in Dallas, has tried cutting back on meals, but with two cats in the house, “he just gobbles…
AstraZeneca‘s failed late-stage trial for Wainua was never expected to have a major financial impact on the company. Most analysts estimate the trial miss wiped just 2-4% from their valuation models. Yet the shares lost roughly twice that in a single session, suggesting the market reaction reflected more than just the loss of one drug,…
Traders work at the New York Stock Exchange on Dec. 29, 2025. NYSE Small-cap U.S. stocks are capping off one of their strongest first halves in decades. But this is not your ordinary small-cap boom led by traditional businesses linked to the economic cycle. This run, like the one going on with their larger-cap peers,…
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the drug’s future. Abivax stock was last trading up 34% at 111.7 euros. The move comes after it crashed…
Public markets are beginning to reopen for biotech companies after several years of muted activity. But the strongest companies may still be more likely to sell themselves to Big Pharma rather than testing investor appetite in an IPO, according to JPMorgan’s top healthcare dealmakers. The IPO window has reopened for high-quality biotech companies, but investors…
Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs. Even so, they’re already outlining their visions for the future of obesity drugs. At the American Diabetes Association’s Scientific Sessions in New Orleans last week, drugmakers pitched doctors and investors on the idea of new shots…
Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it can live up to the hype. Icotyde went to market after the Food and Drug Administration approved it in mid-March for moderate to severe plaque psoriasis. The once-a-day drug is the first…
ILLUSTRATION of hantavirus testing concept with laboratory tubes containing cotton swabs and HANTAVIRUS labels photographed in front of a public domain hantavirus related microscopic image released by the U.S. Centers for Disease Control and Prevention in Paris, France, May 8, 2026. Joao Luiz Bulcao | Afp | Getty Images An outbreak of the hantavirus caused…
